CDNF is a novel drug candidate for the treatment of neurodegenerative diseases. Naturally present in the human blood circulation and cerebrospinal fluid, CDNF is a protein with neuroprotective and neurorestorative properties, patented internationally by Herantis. Encouraged by strong preclinical proof-of-concept Herantis has launched a first-in-human, randomized Phase 1-2 clinical study with CDNF in the treatment of Parkinson's disease (PD). The clinical study has received funding from the European Union's research and innovation program Horizon 2020
Herantis launched the first-in-human clinical study with CDNF in 2017. This Phase 1-2, randomized, placebo-controlled clinical study assesses the safety and initial efficacy of CDNF compared to placebo in 18 patients with Parkinson's disease. The study is conducted at three university hospitals in Finland and Sweden and its patient recruitment is intended to be completed in 2018. More information on the clinical study is available on the project's website at treater.eu/.
The video can be found here:
Potential disease-modifying therapy enters Phase 2
Will Tasigna, an FDA-approved cancer drug, be the first drug to revere symptoms of Parkinson's and dementia? 
Trehalose as a promising therapeutic candidate for the treatment of Parkinson's disease - 2019
